Safeguarding Laboratory Autoverification in Viet Nam: Rule Validation, Exception Handling and Continuous Performance Monitoring

DIAGNOSTIC SAFETY & RISK MANAGEMENTMEASUREMENT, LEARNING & IMPROVEMENT

11/5/202617 min read

Safeguarding Laboratory Autoverification in Viet Nam: Rule Validation, Exception Handling and Continuous Performance Monitoring

A laboratory result can move from an analyzer to a patient's electronic health record within seconds, without a laboratory professional reviewing that individual result. For busy hospitals, this can be a valuable improvement. Clinicians may receive information sooner, while laboratory staff can devote more attention to findings that require closer examination.

But an important question remains: how does the laboratory know that the system made the right decision?

A result may fall within the analytical measurement interval while an instrument warning, an unexpected change from a previous measurement or a problem with the specimen raises concerns about its reliability. If automated rules fail to recognize these circumstances, the same weakness could affect many results before anyone notices.

This is the central challenge of laboratory autoverification. Its purpose is not simply to release results faster or reduce manual workload. It is to establish a dependable process for determining which results can be released automatically, which require professional review and how the laboratory can demonstrate that these decisions remain appropriate over time.

As healthcare organizations in Viet Nam expand laboratory automation and integrate diagnostic information systems, these questions deserve greater attention. Automation can improve efficiency, but its contribution to diagnostic safety depends on the reliability of the decisions it makes and the safeguards surrounding those decisions.

Understanding What Autoverification Can and Cannot Do

Laboratory autoverification uses predefined criteria to determine whether examination results are eligible for automated review and release without individual manual authorization. These criteria may operate within an analyzer, middleware application, laboratory information system (LIS) or a combination of connected systems.

Depending on the examination and laboratory workflow, the rules may evaluate internal quality control status, instrument flags, analytical measurement intervals, specimen interference indicators, relevant patient information, previous results and relationships between different measurements.

Consider a potassium result that falls within the analytical measurement interval but is associated with evidence of hemolysis. Depending on the degree of interference and the laboratory's validated procedures, the result may require additional assessment before release. Another potassium result may fall outside the reference interval but remain analytically reliable and appropriate for automated release under an approved protocol.

These examples illustrate why reference intervals alone are insufficient for determining whether a result can be released automatically. An abnormal result is not necessarily erroneous, while a result within the reference interval is not necessarily free from analytical or procedural concerns.

The purpose of autoverification is to translate appropriate laboratory review decisions into explicit, testable rules. Those rules must reflect the examinations performed, the analytical methods used, the characteristics of the patient population and the information available at the time of result review.

The process also has limitations. Not every unusual finding can be evaluated safely through predefined criteria, and not every clinically important circumstance will be represented in the data available to the system.

For example, an autoverification algorithm may evaluate specimen interference information transmitted by an analyzer, but it cannot reliably identify a specimen identification error that leaves no detectable inconsistency in the available data. Automation should therefore be understood as one component of laboratory quality assurance, not a substitute for safeguards throughout the examination process.

Conventional rule-based autoverification should not automatically be described as artificial intelligence. Most established systems use predefined decision logic rather than machine learning. Although AI-based approaches may be incorporated into laboratory workflows, they introduce additional considerations involving model validation, transparency, performance monitoring and change control.

The relevant question is not how sophisticated the technology appears. It is whether the laboratory can demonstrate that its automated decisions are appropriate for their intended use.

Validating Rules Before Automated Release Begins

The first essential safeguard is establishing that autoverification rules work as intended before they are allowed to release patient results.

ISO 15189:2022 addresses this directly in Clause 7.4.1.5, which concerns automated selection, review, release and reporting of results.

When a laboratory implements such a system, the standard requires a procedure ensuring that the criteria for automated decisions are defined, approved, readily available and understood by personnel responsible for authorizing result release. These criteria must be validated and approved before use, reviewed regularly and verified after relevant changes to the reporting system that could affect correct functioning and place patient care at risk.

The standard also requires results selected for manual review to be identifiable, with relevant information about the review retrievable where appropriate. It further requires the ability to suspend automated processing rapidly when necessary.

These provisions establish important safeguards, but they do not prescribe one universal decision algorithm, validation dataset or acceptable error rate for every laboratory.

CLSI AUTO15, Autoverification of Medical Laboratory Results for Specific Disciplines, provides complementary guidance on designing, validating and implementing autoverification processes. Published in September 2019 and reaffirmed in June 2025, the guideline addresses several laboratory disciplines, including chemistry, hematology, coagulation, immunochemistry, infectious disease testing, toxicology and urinalysis.

Its scope requires careful interpretation. CLSI AUTO15 does not provide directly applicable recommendations for transfusion medicine, microbiology, molecular medicine, anatomic pathology or point-of-care testing. Laboratories working in these areas need to evaluate the technical requirements and professional guidance relevant to their examinations rather than assuming that the guideline applies unchanged.

For examinations included in an autoverification program, validation needs to assess more than whether the software correctly processes routine results.

The laboratory should establish how the system behaves when internal quality control is unacceptable, an analyzer generates a warning, specimen interference is detected, a result exceeds an approved decision limit or essential information is unavailable. It should also evaluate clinically relevant differences between current and previous results, unexpected relationships between analytes and circumstances in which several rules are triggered simultaneously.

Validation may use appropriately selected historical results, simulated cases, deliberately constructed challenge scenarios and prospective comparisons with established laboratory review procedures before automatic release is enabled.

Routine historical datasets are useful, but they may not adequately represent rare events with potentially serious consequences. A large dataset containing mostly straightforward results can produce reassuring overall agreement while offering limited evidence about how the system handles unusual interference, missing information or combinations of findings that should prevent automatic release.

For this reason, deliberately designed challenge scenarios can complement retrospective testing.

Independent professional assessment remains important. Agreement between automated decisions and an existing manual review process provides useful evidence, but the reference process itself must be sufficiently reliable. When automated and manual decisions disagree, the laboratory should investigate the discrepancy rather than automatically treating the software or the human reviewer as incorrect.

Validation records should identify the examinations covered, rule versions, test scenarios, expected outcomes, observed decisions, discrepancies, corrective actions and responsible approvers.

A successful technical installation demonstrates that system components can function. It does not, by itself, establish that automated result release is sufficiently reliable for clinical use.

Exception Handling Is a Patient Safety Safeguard

A dependable autoverification system must recognize when a result should not be released automatically.

These situations are commonly described as exceptions. They may arise from analytical uncertainty, unacceptable quality control, instrument warnings, missing information, unusual result patterns or other circumstances specified in the laboratory's approved rules.

How these exceptions are handled deserves as much attention as the rules governing automatic release.

When a result is held, its status should be visible to authorized laboratory personnel. Where technically feasible, the system should indicate why the result was held so that the reviewer can determine what further assessment is necessary.

The laboratory needs to establish how exceptions are prioritized, who is authorized to review them, what information is required for resolution and when escalation is appropriate.

A result held in an electronic review queue is not necessarily safer if nobody examines it within an appropriate timeframe. Unresolved exceptions can cause reporting delays, particularly when examination results are needed for urgent clinical decisions.

The response should therefore reflect the nature of the concern. Not every held result requires repeat analysis. Some exceptions can be resolved by reviewing quality control records, specimen information, previous results or instrument documentation. Others may require additional testing, consultation with clinical staff or collection of a new specimen.

Delta checks illustrate why professional judgment remains necessary.

A delta check compares a current measurement with an earlier result from the same patient to identify a change that may require investigation. Its significance depends on the analyte, the time between measurements, analytical performance, biological variation and the patient's clinical circumstances.

A substantial difference may reflect a genuine change in the patient's condition rather than a laboratory error. Conversely, a smaller change may be important for a particular analyte or clinical situation. Applying identical delta-check thresholds across unrelated examinations or patient populations can therefore lead to unnecessary holds or missed concerns.

Critical results require additional attention. Automatic release into a laboratory information system does not demonstrate that a critical finding has reached the appropriate clinician. Where critical results are eligible for autoverification, the laboratory must still fulfill applicable notification, documentation and escalation requirements through its established reporting procedures.

These responsibilities should not be considered complete simply because an electronic result was successfully transmitted.

Exception handling also needs safeguards against inappropriate manual overrides. When an authorized professional releases a result that the automated system has held, the reason for that decision should be documented according to the laboratory's procedures.

The objective is to preserve timely reporting while ensuring that uncertain or potentially unreliable findings receive appropriate professional attention.

Why Previously Validated Rules Can Become Unreliable

A common assumption is that a validated autoverification system will remain dependable as long as its programmed rules are not deliberately changed.

In practice, the environment surrounding those rules can change considerably.

A laboratory may introduce a different analyzer, modify an analytical method, change reagent or calibrator lots, revise reference intervals or update specimen handling procedures. Software upgrades can alter the way information moves between analyzers, middleware and the laboratory information system.

Changes in patient populations, examination patterns or clinical service arrangements may also influence whether previously established decision limits remain appropriate.

Not every change requires complete revalidation of the entire system. However, changes with the potential to affect automated decisions should undergo appropriate risk assessment and, where justified, verification or revalidation.

Some of the most consequential problems may be difficult to recognize because the numerical results continue to appear plausible.

For example, an interface modification could prevent an important analyzer warning from reaching the autoverification software. A revised test identifier might cause a rule to be applied to the wrong examination. An incorrect unit conversion could alter the clinical meaning of a result without producing an obvious technical failure.

A system may continue transmitting results successfully while making decisions based on incomplete or incorrectly interpreted information. Checking that connected systems remain operational is therefore not enough to establish that automated decisions remain reliable.

A 2026 review by Li and colleagues, published in Laboratory Medicine, proposes a structured approach to managing laboratory information system-based autoverification rules throughout their operational life cycle.

The framework emphasizes identifying changes that may affect rule performance, assessing their risks, conducting proportionate verification or revalidation, maintaining version control and continuously monitoring automated decisions.

The publication is a standards-informed review proposing a governance framework, not an experimental study demonstrating improved patient outcomes. Its contribution is to describe how laboratories can manage risks that emerge after initial implementation.

These principles are consistent with ISO 22367:2026, Medical Laboratories: Application of Risk Management to Medical Laboratories, published in April 2026.

The second edition addresses the identification, estimation, evaluation, control and monitoring of risks associated with medical laboratory examinations and services. Its scope covers pre-examination, examination and post-examination activities, including accurate transmission of examination results into electronic medical records.

ISO 22367:2026 does not prescribe one universally acceptable risk level or extend its requirements to the clinical decisions made by treating professionals after the laboratory examination.

For autoverification, these principles support a risk-based approach to managing system changes.

A laboratory should be able to determine which rule version was active at a particular time, what modifications were made, why they were introduced, how they were evaluated and who authorized their implementation.

Where appropriate, changes should be tested before deployment against documented acceptance criteria. The laboratory should also have an arrangement for reversing unsuccessful modifications or suspending affected rules when unexpected behavior is identified.

An important consideration is what happens when automation cannot be trusted.

The laboratory may need to disable affected rules temporarily, direct results to authorized manual review and investigate whether previously released results were affected. Essential reporting services should remain available through appropriate contingency procedures, including during software failures, interface interruptions or planned maintenance.

A system that can release large numbers of results automatically but cannot be suspended promptly when necessary is difficult to govern safely.

Monitoring More Than the Autoverification Rate

The percentage of results released automatically is one of the most visible measures of an autoverification program.

It can help describe the extent of automation, manual workload and operational efficiency. However, a higher autoverification rate does not necessarily indicate greater accuracy or patient safety.

A system that automatically releases nearly every result may be highly efficient, but it may also contain rules that fail to recognize important exceptions. The percentage alone cannot distinguish between these possibilities.

Performance monitoring should therefore consider the appropriateness of automated decisions, not only how frequently automation is used.

Two useful concepts are false passes and false holds.

For evaluation purposes, a false pass occurs when the autoverification system accepts a result for automatic release even though an appropriate reference assessment determines that it should have been held for further review.

A false hold occurs when the system prevents automatic release of a result that could have been released under the established reference criteria.

These concepts help laboratories evaluate decision reliability, but they require clearly defined reference criteria, denominators and methods for resolving disagreements.

A false pass may expose clinicians to a result that should have received additional scrutiny. A false hold may increase workload and delay reporting without providing a corresponding safety benefit.

Their consequences are not necessarily equivalent. The laboratory should consider both how often they occur and the potential clinical significance of the circumstances involved.

The framework proposed by Li and colleagues in 2026 includes reference-adjudicated measures of false passes and false holds as part of continuous performance assurance. These are proposed evaluation measures, not universal numerical thresholds mandated by ISO 15189.

A practical monitoring program may combine periodic review of automatically released results, assessment of held-result queues, targeted testing of high-risk scenarios and investigation of discrepancies identified after reporting.

The laboratory should also examine changes in autoverification rates across analytes, examination groups, instruments and relevant clinical settings. An unexpected shift in the proportion of automatically released results may reflect changes in patient characteristics, analytical performance, rule behavior or the transmission of information between systems.

Monitoring only an overall laboratory-wide rate can obscure these differences.

Turnaround time remains an important operational measure, particularly for examinations supporting urgent clinical decisions. It should be assessed using consistent definitions and appropriate distinctions between emergency and routine testing.

Another useful governance measure is the proportion of rule changes that undergo documented risk assessment and appropriate testing before deployment.

Results that remain in manual review queues beyond the laboratory's established expectations also deserve attention. Monitoring these delays can reveal whether automated processing has simply moved workload into another part of the reporting pathway.

Performance data become useful when they lead to action.

A recurring exception may indicate that a rule is unnecessarily restrictive. An unexpected automatic release may require investigation, assessment of potentially affected results, corrective action and additional safeguards before automation resumes.

The purpose is not to produce an impressive automation dashboard. It is to demonstrate that the laboratory understands how its automated decisions perform and can recognize when those decisions become unreliable.

What Recent Research Tells Us

Published studies support the potential of autoverification to improve laboratory efficiency. Their findings, however, need to be interpreted within the clinical and operational settings in which they were obtained.

A study by Miler and colleagues, published online in December 2024 and appearing in Clinical Chemistry and Laboratory Medicine in 2025, proposed a systematic approach to verifying automated review, release and reporting decisions.

The investigators used retrospective laboratory information system data and incorporated an assessment of potential patient safety risks. Their work illustrates why laboratories need to evaluate automated decisions against an appropriate reference process rather than relying solely on the percentage of results released automatically.

The proposed method does not establish a universal rule set or acceptable error rate for every laboratory.

More recently, a study by Çinpolat, published in the Journal of Medical Biochemistry in 2026, evaluated autoverification for clinical chemistry and immunoassay examinations in a tertiary care hospital laboratory in Türkiye.

The study reported that approximately 71% of individual test results were autoverified, while the proportion calculated at the specimen tube level was 21%.

This difference is important because the denominator changes the meaning of the performance measure. A specimen tube may contain several requested tests, some of which are eligible for automatic release while others require manual review.

The investigators also reported reductions in median turnaround time of six minutes for emergency examinations and 12 minutes for routine examinations. The overall proportion of results exceeding predefined turnaround-time targets decreased from 6.4% before implementation to 5.8% afterward.

These findings suggest that appropriately configured autoverification can improve reporting efficiency in a laboratory with validated decision rules and an integrated information system.

However, the results reflect one institution's examination mix, patient population, technology and operational arrangements. They should not be presented as benchmark autoverification rates or recommended turnaround-time targets for laboratories in Viet Nam.

A reduction in reporting time does not, by itself, establish that diagnostic errors have decreased or that clinical outcomes have improved.

The 2026 review by Li and colleagues addresses a related but different question. Rather than demonstrating the clinical effectiveness of a particular implementation, it proposes a framework for maintaining the reliability of autoverification rules as laboratory conditions change.

Taken together, these publications support a practical conclusion. Automation can improve efficiency, but reliable performance depends on validated decision criteria, appropriate handling of exceptions, disciplined change management and continued professional oversight.

Applying International Standards in Viet Nam

Autoverification is increasingly relevant to healthcare organizations in Viet Nam as laboratory analyzers, information systems and electronic medical records become more closely integrated.

However, laboratories differ in examination volumes, analytical equipment, staffing arrangements, information technology capabilities and the maturity of their quality management systems. These differences affect whether autoverification is appropriate and how it should be implemented.

Viet Nam's national standard TCVN ISO 15189:2025, Medical Laboratories: Requirements for Quality and Competence, is identical to ISO 15189:2022 and replaces TCVN ISO 15189:2014.

It provides a relevant quality and competence framework for medical laboratories, including those implementing automated selection, review and release of examination results.

Nevertheless, the existence of this standard does not mean that every medical laboratory in Viet Nam is legally required to implement autoverification.

A distinction must be maintained between statutory obligations, national standards, international professional guidance and requirements associated with particular accreditation or contractual commitments.

Circular No. 01/2013/TT-BYT of the Ministry of Health establishes requirements relating to laboratory quality management at healthcare facilities.

It remains relevant as amended, including by Circular No. 25/2026/TT-BYT, issued on June 30, 2026. The amendment concerning Circular No. 01/2013/TT-BYT took effect on August 15, 2026 and revised provisions encouraging healthcare facilities to participate in relevant external quality assessment programs, including recognized international programs.

The amendment did not establish a general obligation to use autoverification.

Healthcare organizations should also consider the Law on Medical Examination and Treatment No. 15/2023/QH15 and relevant implementing regulations according to their licensed services and professional responsibilities.

The use of automated software does not remove the need for appropriate laboratory quality management, clinical governance and professional accountability.

Digital result management also involves the processing of personal health information.

Viet Nam's Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/ND-CP took effect on January 1, 2026.

Laboratories should consider the applicable requirements concerning lawful processing, confidentiality, authorized access, information security and the handling of identifiable patient information within connected laboratory systems.

Validation activities using historical patient records may also involve personal data protection obligations, depending on how information is obtained, processed, stored and shared. The use of simulated data does not eliminate these obligations if the underlying information remains identifiable or can reasonably be linked to an individual.

Where external software providers or technology partners support autoverification, healthcare organizations should establish clear responsibilities for system configuration, software changes, access permissions, technical support and incident handling.

A technology provider may be responsible for software functionality, but installing a commercial product does not automatically transfer the laboratory's professional responsibilities for result release and quality management to the vendor.

Laboratory leadership needs to ensure that the system is appropriate for its intended use and that competent, authorized personnel oversee validation, implementation and continued operation.

These arrangements should reflect the laboratory's actual services, technical capabilities, patient population and applicable legal and professional requirements.

Building a Controlled Autoverification Program

Healthcare organizations do not need to automate a large examination menu immediately to benefit from autoverification.

A limited, carefully selected starting scope may be more manageable, particularly for laboratories introducing automated result release for the first time.

Initial implementation can focus on examinations with stable analytical processes, reliable information availability and sufficient resources for rule development and validation.

The laboratory should begin by understanding how results are currently reviewed, which decisions can be translated into consistent automated criteria and which circumstances require professional judgment.

Rule development should involve laboratory professionals with appropriate expertise, supported by information technology personnel and relevant vendors. The rules need to be tested against routine and challenging scenarios before automated release is enabled.

Early operational monitoring should examine discrepancies, exception volumes, turnaround times and staff workload. Unexpected decisions should be investigated before expanding the program.

As additional examinations are introduced, governance arrangements should remain consistent. Each rule should have a defined purpose, an identified owner, documented approval and a process for reassessment when relevant changes occur.

Staff training needs to extend beyond learning how to operate the software.

Laboratory personnel should understand why results are held, how exceptions are reviewed, when additional testing or communication is necessary and how to respond when automated processing becomes unavailable or behaves unexpectedly.

Authorized personnel should also have a practical way to suspend automated release when safety concerns arise.

Contingency procedures are especially important when result reporting must continue during system downtime or while potentially affected rules are being investigated.

The laboratory may benefit from reviewing selected cases in which automated decisions were later questioned, even when no patient harm was identified. Such reviews can reveal weaknesses that are not apparent from routine performance indicators.

Where changes are introduced, the laboratory should evaluate whether the revised process improves decision reliability without creating unnecessary manual work or reporting delays.

The most effective improvement may involve correcting a small number of poorly performing rules rather than expanding automation to more examinations.

A sustainable program connects professional accountability, rule validation, risk management, information governance and continuous quality improvement.

From Faster Results to More Reliable Diagnostic Decisions

Autoverification can reduce repetitive manual work and help laboratories deliver examination results more efficiently.

Its clinical value, however, depends on whether the laboratory can demonstrate that automatic release occurs under appropriate conditions.

A result should not be released automatically simply because it falls within an expected numerical interval. The system must also consider relevant quality control information, analytical warnings, specimen-related concerns and other criteria established through validation.

When those conditions are not satisfied, the laboratory needs a dependable pathway for professional review.

ISO 15189:2022, ISO 22367:2026 and CLSI AUTO15 provide complementary foundations for controlling these processes. Recent research adds evidence that autoverification can improve operational efficiency while highlighting the importance of maintaining reliable rules as laboratory methods, information systems and clinical circumstances evolve.

For healthcare organizations in Viet Nam, the priority should not be to maximize the percentage of automatically released results.

It should be to establish a system in which routine, appropriately evaluated results move efficiently, exceptions receive timely professional attention and changes that could compromise automated decisions are recognized and addressed.

Diagnostic excellence in laboratory autoverification is not demonstrated by how many results a system releases automatically. It depends on whether the laboratory can establish, and continue to demonstrate, that those results are released under validated conditions, with appropriate safeguards whenever professional review is necessary.

Selected References and Regulatory Sources

International Organization for Standardization. ISO 15189:2022: Medical Laboratories — Requirements for Quality and Competence. Fourth edition. Particularly Clause 7.4.1.5, Automated Selection, Review, Release and Reporting of Results.

International Organization for Standardization. ISO 22367:2026: Medical Laboratories — Application of Risk Management to Medical Laboratories. Second edition. April 2026.

Clinical and Laboratory Standards Institute. AUTO15: Autoverification of Medical Laboratory Results for Specific Disciplines. First edition. September 11, 2019. Reaffirmed June 2025.

Clinical and Laboratory Standards Institute. AUTO10-A: Autoverification of Clinical Laboratory Test Results. 2006. Archived guideline.

Li Z, Cui L, Feng Y, Feng S. Change Management and Continuous Assurance of Laboratory Information System-Based Autoverification Rules Aligned With ISO 15189:2022: A Practical Framework for Clinical Laboratories. Laboratory Medicine. 2026;57(5). Published online September 7, 2026. DOI: 10.1093/labmed/lmag060.

Çinpolat HY. The Effect of Auto-Verification on Turnaround Time for Clinical Chemistry and Immunoassay Tests. Journal of Medical Biochemistry. 2026;45(6):1342–1353. DOI: 10.5937/jomb0-61380.

Miler M, Nikolac Gabaj N, Šimić G, et al. Verification of Automated Review, Release and Reporting of Results With Assessment of the Risk of Harm for Patients: The Procedure Algorithm Proposal for Clinical Laboratories. Clinical Chemistry and Laboratory Medicine. 2025;63(6):1109–1117. Published online December 30, 2024. DOI: 10.1515/cclm-2024-1164.

Ministry of Science and Technology of Viet Nam. TCVN ISO 15189:2025: Medical Laboratories — Requirements for Quality and Competence. Promulgated under Decision No. 561/QD-BKHCN dated April 14, 2025. Identical to ISO 15189:2022, replacing TCVN ISO 15189:2014.

Ministry of Health of Viet Nam. Circular No. 01/2013/TT-BYT, Guiding the Implementation of Laboratory Quality Management at Medical Examination and Treatment Facilities. January 11, 2013, as amended.

Ministry of Health of Viet Nam. Circular No. 25/2026/TT-BYT, Amending and Supplementing Certain Provisions of Circular No. 01/2013/TT-BYT and Other Ministry of Health Circulars. June 30, 2026. Relevant amendment effective August 15, 2026.

National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15, as amended.

National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. Effective January 1, 2026.

Government of Viet Nam. Decree No. 356/2025/ND-CP, Detailing Certain Provisions and Measures for Implementing the Law on Personal Data Protection. Effective January 1, 2026.

Professional Scope and Disclaimer

This article is published by Diagnostic Excellence Vietnam (DxEx.vn), a professional initiative dedicated to advancing diagnostic quality, safety and reliability in Viet Nam through evidence-informed knowledge sharing, risk management, measurement and quality improvement.

The content is intended for general professional education and discussion. It does not constitute patient-specific medical advice, a clinical or laboratory diagnosis, an individualized recommendation concerning autoverification rules, decision thresholds, validation methods, exception handling, result release or clinical management, a determination of professional or technical error, an accreditation assessment, certification of a laboratory information system or legal advice.

References to ISO, CLSI and other international standards or professional guidance do not imply that their requirements are automatically mandatory under Vietnamese law. Their applicability depends on the laboratory's services, professional responsibilities, accreditation commitments, contractual arrangements and relevant legal requirements.

Decisions concerning autoverification design, validation, implementation, monitoring, result reporting and corrective action must be undertaken by appropriately qualified and authorized laboratory professionals in accordance with applicable Vietnamese law, relevant standards, approved procedures and the laboratory's actual operational circumstances.

Diagnostic Excellence Vietnam does not provide laboratory testing, clinical diagnosis, treatment or certification of laboratory software systems through this educational publication.